a Department of Orthopaedic Surgery, Sidney Kimmel Medical School , Thomas Jefferson University , Philadelphia , PA , USA.
b Hand Surgery Division , The Rothman Institute at Thomas Jefferson University , Philadelphia , PA , USA.
Connect Tissue Res. 2019 Jan;60(1):10-20. doi: 10.1080/03008207.2018.1512979. Epub 2018 Sep 7.
Tendon injuries of the hand that require surgical repair often heal with excess scarring and adhesions to adjacent tissues. This can compromise the natural gliding mechanics of the flexor tendons in particular, which operate within a fibro-osseous tunnel system similar to a set of pulleys. Even combining the finest suture repair techniques with optimal hand therapy protocols cannot ensure predictable restoration of hand function in these cases. To date, the majority of research regarding tendon injuries has revolved around the mechanical aspects of the surgical repair (i.e. suture techniques) and postoperative rehabilitation. The central principles of treatment gleaned from this literature include using a combination of core and epitendinous sutures during repair and initiating motion early on in hand therapy to improve tensile strength and limit adhesion formation. However, it is likely that the best clinical solution will utilize optimal biological modulation of the healing response in addition to these core strategies and, recently, the research in this area has expanded considerably. While there are no proven additive biological agents that can be used in clinical practice currently, in this review, we analyze the recent literature surrounding cytokine modulation, gene and cell-based therapies, and tissue engineering, which may ultimately lead to improved clinical outcomes following tendon injury in the future.
手部肌腱损伤需要手术修复,常伴有过多的瘢痕和与邻近组织的粘连。这尤其会影响屈肌腱的自然滑动力学,屈肌腱在类似于一组滑轮的纤维 - 骨隧道系统中运行。即使将最精细的缝合修复技术与最佳手部治疗方案相结合,也不能确保在这些情况下可预测地恢复手部功能。迄今为止,大多数关于肌腱损伤的研究都集中在手术修复的力学方面(即缝合技术)和术后康复。从文献中得出的治疗的核心原则包括在修复过程中使用核心和腱周缝线的组合,并在手治疗早期开始运动,以提高拉伸强度并限制粘连形成。然而,很可能最佳的临床解决方案将除了这些核心策略之外,还利用对愈合反应的最佳生物学调节,最近,该领域的研究有了相当大的扩展。虽然目前没有经过验证的可在临床实践中使用的附加生物制剂,但在本综述中,我们分析了围绕细胞因子调节、基因和基于细胞的治疗以及组织工程的最新文献,这些研究可能会在未来导致肌腱损伤后的临床结果得到改善。